PO-1267 Pulmonary toxicities after chemoradiation followed by durvalumab for stage III NSCLC: a real setting. (May 2022) - Nicolet, C.; Briot, N.; Amoyal, C.; Chevalier, C.; Jeandidier, C.; Kaderbhai, C.; Foucher, P.; Westeel, V.; Martin, E.